Clinical trial · no report yet · Phase 2
CLL2-BZAG
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL
- NCT04515238 ↗
- Active, not recruiting
- German CLL Study Group
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Podcasts | 2 | |
| YouTube | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL (CLL2-BZAG Protocol)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Chronic Lymphoid Leukemia
- Interventions
- Bendamustine; Obinutuzumab; Zanubrutinib; Venetoclax
- Arms
- BZAG · Experimental
- Enrollment
- 42
- Primary outcomes
- Negativity rate of minimal residual disease (MRD) in peripheral blood (PB) measured by multi-color flow cytometry
- Sponsor
- German CLL Study Group
- Start
- Oct 1, 2020
- Primary completion
- Feb 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04515238 · updated Aug 20, 2026
Publications
linked from the registry- Furstenau M, Robrecht S, Schneider C, Tausch E, Giza A, Ritgen M, Bittenbring J, Hebart H, Schottker B, Illert AL, Graeven U, Stoltefuss A, Heinrich B, Eckert R, Fink A, Stumpf J, Fischer K, Al-Sawaf O, Simon F, Kleinert F, Weiss J, Kreuzer KA, Schilhabel A, Bruggemann M, Langerbeins P, Stilgenbauer S, Eichhorst B, Hallek M, Cramer P. MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial. Blood. 2025 Mar 20;145(12):1282-1292. doi: 10.1182/blood.2024026685. PubMed 39883943